RE: Oxford Nanopore Public Listing30 Mar 2021 17:27
@neilrich3
I mean you look at this and you can argue, ok well what about revenues in three years time? BUT Novacyt have already confirmed that earnings will be north of 60m minimum and that alone should give us a better mcap than where we are today? FACT.
Any contract or perhaps confirmation of that Genome Assay being used to detect VOCs and as part of a Diagnostics culture to protect against future pandemics will give us the longevity confirmation we need. Hopefully, that should be the end of any share price sub £10 ?
Then you look at Perkin Elmer and its 14 bn valuation and you think, Ok i realise its not apples with apples but for crying out loud they are on X 40 earnings and we are surely worth more than x2 EBITDA. In fact our valuation is worse than X2 EBITDA due to the amount of cash at bank being built. Its probably more like X1.5
The SP has to give at some point.... its crazy.
GLA